Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer

Surgery Today

Volumn 34, Issue 11, 2004, Pages 896-901

  Suemitsu, Ryuichi ^a   Yoshino, Ichiro ^a   Tomiyasu, Makiko ^a   Fukuyama, Seiichi ^a   Okamoto, Tatsuro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Area under the curve; Receiver operating characteristic curve; Screening marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG RESECTION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 14744275382     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00595-004-2853-y     Document Type: Article

References (29)

1. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
2. Cox G, Steward WP, O'Byrne KJ. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 1999;54:169-79.
3. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-74.
4. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survial in mice. Hum Gene Ther 2001;12:515-26.
5. Yamauchi K, Ogata Y, Nagase H, Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 2001;31:791-8.
6. Lein M, Jung K, Laube C, Hubner T, Winkelmann B, Stephan C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000;85:801-4.
7. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, et al. World Health Organization. Histological typing of lung and pleural tumours. 3rd ed. Berlin: Springer; 1999.
8. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225-33.
9. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
10. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
11. Galateau-Salle FB, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, et al. Matrix metalloproteinasae and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000;31:296-305.
12. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000;190:150-6.
13. Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S, et al. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 2003;98:1822-9.
14. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311-6.
15. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085-92.
16. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503.
17. Pellegrini P, Contasta I, Berghella AM, Gargano E, Mammarella C, Adorno D. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer. Cancer Immunol Immunother 2000;49:388-94.
18. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999;19:1589-92.
19. Suzuki M, Lizasa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H, et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small cell lung cancer. Invas Metastas 1999;18:134-41.
20. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992;66: 1184-94.
21. Lizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinases 9 in non-small lung cancer patients. Clin Cancer Res 1999;5:149-53.
22. Birkedal-Hansen H, Moore WG, Bodden MK, Windson LJ, Birkedal-Hansen B, DeCario A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
23. Nagase H. Activation mechanisms of matrix metalloproteinases. J Biol Chem 1997;378:151-60.
24. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 1995;270:5331-8.
25. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total level of tissue inhibitor of metalloproteinases 1 in plasma yields high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156-64.
26. Fong KM, Kida Y, Zimmermann PV, Smith PJ. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996;2:1369-72.
27. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula UL, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-7.
28. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgius N, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118-21.
29. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-9.